AI pharmaceutical company XtalPi Holdings Ltd. (2228.HK) on Monday announced it has entered into a strategic cooperation memorandum with Microsoft China for new drug and materials development. Under the tie-up, the two parties will use cutting-edge technologies such as AI, large models and robotic laboratories to collaborate and explore innovative applications of such technologies in biopharmaceuticals and material sciences.
As part of this collaboration, XtalPi will use its AI for Science platform in conjunction with Microsoft’s large language model (LLM) capabilities, including those associated with its Azure OpenAI and high-performance cloud computing platform, to explore vertical domain large models in the fields of drug discovery and new material development. Additionally, XtalPi plans to deploy its proprietary AI-driven molecular generation and molecular dynamics calculation tools on the Microsoft Azure cloud platform.
Founded in 2015 and formerly known as QuantumPharm, XtalPi is an innovative R&D platform using quantum physics, AI-driven technologies and robotic systems for drug development. It offers solutions for industries such as pharmaceuticals and material sciences. It’s also the first company to list in Hong Kong under a special rule that relaxes listing requirements for certain tech companies with strong potential. After the announcement, XtalPi’s stock surged 21.3% to close at HK$4.78 on Monday.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here
